98 results
Page 2 of 5
8-K
EX-99.1
qlp3n6g2nhg4
9 Jul 21
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
4:02pm
8-K
EX-99.1
8uals6x
15 Jun 20
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
5:25pm
8-K
EX-99.1
fgje9k63gu50 sdxt
12 May 20
Vaxart Announces First Quarter 2020 Financial Results
4:04pm
8-K
EX-99.1
xnn6cmi m837ynqrw2
29 Apr 20
Vaxart Announces Corporate Update for First Quarter 2020
12:00am
8-K
EX-99.2
0plph9z
19 Mar 20
Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results
4:04pm
8-K
EX-99.1
zmnl dpszvr4u99p
19 Mar 20
Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results
4:04pm
8-K
EX-99.1
r6rptxa
2 Mar 20
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
2:48pm
424B5
isnfdvu0sznoyd
2 Mar 20
Prospectus supplement for primary offering
11:44am
8-K
EX-99.1
dpsc tu2rcgqw
12 Nov 19
Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update
4:56pm
424B4
31zebrs dmrcqc
27 Sep 19
Prospectus supplement with pricing info
4:32pm